

Datasheet: MCA2459FT

Description:	MOUSE ANTI HUMAN CD138:FITC
Specificity:	CD138
Other names:	SYNDECAN-1
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	B-A38
Isotype:	IgG1
Quantity:	25 µg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	■			Neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	FITC	490	525
Preparation	Purified IgG prepared by ion exchange chromatography		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% Sodium Azide		
Stabilisers	1% Bovine Serum Albumin		
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml		
Immunogen	U266 cell line.		
External Database Links	UniProt: P18827 Related reagents		

Entrez Gene:[6382](#) SDC1 [Related reagents](#)**Synonyms**

SDC

Fusion Partners

Spleen cells from immunized Balb/c (Iffa Credo) mice were fused with cells of the mouse X63/Ag.8653 myeloma cell line.

Specificity

Mouse anti human CD138 antibody, clone B-A38 recognizes human CD138, also known as Syndecan-1 (SDC-1). CD138 is a member of the transmembrane heparan sulfate proteoglycan family ([O'Connell et al. 2004](#), [Sanderson et al. 2008](#)). It is composed of a core protein (comprising 3 domains; a short cytoplasmic domain, a transmembrane domain, and a long extracellular domain) and covalently attached heparan sulfate chains ([Sanderson et al. 2008](#)).

Syndecan-1 is expressed on the surface of plasma cells within the hematopoietic system and on the surface of mature epithelial cells ([O'Connell et al. 2004](#)). It acts as an extracellular matrix receptor, involved in many cellular functions, including cell binding, cell signaling and cytoskeletal organization through cell-cell adhesion and cell-matrix adhesion ([Sanderson et al. 2008](#)).

Flow Cytometry

Use 10ul of the suggested working dilution to label 10⁶ cells in 100ul.

References

1. Borset, M. *et al.* (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. [Br J Haematol. 85 \(3\): 446-51.](#)
2. Du, S. *et al.* (2010) Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. [Int J Clin Exp Pathol. 3 \(4\): 448-57.](#)
3. Kylänpää, L. *et al.* (2009) Syndecan-1 and tenascin expression in cystic tumors of the pancreas. [JOP. 10 \(4\): 378-82.](#)
4. Beauvais, D.M. *et al.* (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. [J Exp Med. 206: 691-705.](#)
5. Beauvais, D.M. and Rapraeger, A.C. (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation [J Cell Sci. 123: 3796-807.](#)
6. Kim, Y.C. *et al.* (2010) Presence of *Porphyromonas gingivalis* and plasma cell dominance in gingival tissues with periodontitis. [Oral Dis. 16: 375-81.](#)
7. Chang, H. *et al.* (2010) CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. [Haematologica. 95: 1542-7.](#)
8. Mahshid Y *et al.* (2009) High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes. [BMC Immunol. 10: 2.](#)
9. Guedez, L. *et al.* (2005) Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. [Blood. 105: 1660-8.](#)
10. Li, K. *et al.* (2010) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. [Int J Clin Exp Pathol. 4: 190-6.](#)
11. Yang, Y. *et al.* (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. [Blood. 110: 2041-8.](#)
12. Thauvat, O. *et al.* (2010) Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. [J Immunol. 185: 717-28.](#)
13. Cannizzo, E. *et al.* (2012) The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. [Am J Clin Pathol. 137 \(3\): 377-86.](#)
14. Li, K. *et al.* (2012) A rare and unique case of aggressive IgE-γ plasma cell myeloma in a

- 28-year-old woman presented initially as an orbital mass. [Hum Pathol. 43: 2376-84.](#)
15. Christianson, H.C. *et al.* (2013) Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. [Proc Natl Acad Sci U S A. 110 \(43\): 17380-5.](#)
16. Malminen, M. *et al.* (2002) Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis. [BMC Dermatol. 2: 10.](#)
17. Itoua Maïga, R. *et al.* (2014) Flow cytometry assessment of *in vitro* generated CD138+ human plasma cells. [Biomed Res Int. 2014: 536482.](#)
18. Di Niro, R. *et al.* (2016) Responsive population dynamics and wide seeding into the duodenal lamina propria of transglutaminase-2-specific plasma cells in celiac disease. [Mucosal Immunol. 9 \(1\): 254-64.](#)
19. Yigit, N. *et al.* (2015) Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. [Hum Pathol. 46 \(8\): 1217-25.](#)
20. Lum, D. & Wong, K.P. (2006) Sarcomatoid plasmacytoma: a diagnosis not often considered. [Pathology. 38 \(6\): 593-6.](#)
21. Gill, J. *et al.* (2009) A case of hyperIgG4 disease or IgG4-related sclerosing disease presenting as retroperitoneal fibrosis, chronic sclerosing sialadenitis and mediastinal lymphadenopathy. [Pathology. 41 \(3\): 297-300.](#)
22. Adepu, S. *et al.* (2015) Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding. [Am J Physiol Renal Physiol. 309 \(2\): F137-45.](#)
23. Hara, S. *et al.* (2016) Distribution and components of interstitial inflammation and fibrosis in IgG4-related kidney disease: Analysis of autopsy specimens [Hum Pathol. May 28 \[Epub ahead of print\]](#)
24. Hosseini, A. *et al.* (2016) Morphometric analysis of inflammation in bronchial biopsies following exposure to inhaled diesel exhaust and allergen challenge in atopic subjects. [Part Fibre Toxicol. 13: 2.](#)
25. Uenoyama, A. *et al.* (2016) Effects of C-xylopyranoside derivative on epithelial regeneration in an *in vitro* 3D oral mucosa model. [Biosci Biotechnol Biochem. 80 \(7\): 1344-55.](#)
26. Hourai, R. *et al.* (2017) IgG4-positive cell infiltration in various cardiovascular disorders - results from histopathological analysis of surgical samples. [BMC Cardiovasc Disord. 17 \(1\): 52.](#)
27. Nagata, K. *et al.* (2017) Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease. [Viral Immunol. Mar 23. \[Epub ahead of print\]](#)
28. Tran, D.N. *et al.* (2017) Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations. [Cytometry B Clin Cytom. 92 \(2\): 136-144.](#)

Further Reading

1. Anttonen, A. *et al.* (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. [Br J Cancer. 79 \(3-4\): 558-64.](#)
2. O'Connell, F.P. *et al.* (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. [Am J Clin Pathol. 121:254-63.](#)
3. Sanderson, R.D. *et al.* (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. [Clin Exp Metastasis. 25:149-59.](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Shelf Life	18 months from date of despatch.
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: 10041: https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf
Regulatory	For research purposes only

Related Products

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M301297:170109'

Printed on 19 May 2018

© 2018 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)